Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.70 |
| ▸ | MEN1 | O00255 | 7/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.58 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.58 |
| ▸ | DHODH | Q02127 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14518623 | 0.85 | MEN1 (0.72) | KDM4EMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL72379 | 0.84 | KDM4E (0.70) | KDM4EMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL12903095 | 0.84 | KDM4E (0.70) | KDM4EMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL31295407 | 0.84 | KDM4E (0.70) | KDM4EMEN1KMT2AALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL4562712 | 0.83 | MEN1 (0.69) | KDM4EMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL1229307 | 0.83 | KDM4E (0.68) | KDM4EMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL7487026 | 0.83 | KDM4E (0.68) | KDM4EMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL17434216 | 0.83 | KDM4E (0.68) | KDM4EMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL10120201 | 0.83 | KDM4E (0.68) | KDM4EMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL6586825 | 0.83 | KDM4E (0.68) | KDM4EMEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117447399-A | Naphthalene formylhydrazine compound and preparation method and application thereof | 上海应用技术大学 | 2024-01-26 | — | — | CN | claimed |
| CN-117447399-A | Naphthalene formylhydrazine compound and preparation method and application thereof | 上海应用技术大学 | 2024-01-26 | — | — | CN | disclosed |
| CN-113024551-B | Compound extracted and separated from brucea javanica, and preparation method and application thereof | 江西中医药大学 | 2021-08-06 | — | — | CN | disclosed |
| CN-113024551-A | Novel compound extracted and separated from brucea javanica, and preparation method and application thereof | 江西中医药大学 | 2021-06-25 | — | — | CN | disclosed |
| EP-1838696-B1 | NOVEL CYANOGUANIDINE COMPOUNDS | LEO PHARMA AS (DK) | 2016-03-09 | — | — | EP | disclosed |
| US-8969573-B2 | Compounds for the inhibition of cellular proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969573-B2 | Compounds for the inhibition of cellular proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969573-B2 | Compounds for the inhibition of cellular proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130178505-A1 | Compounds for the Inhibition of Cellular Proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178505-A1 | Compounds for the Inhibition of Cellular Proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-11 | — | — | US | disclosed |
| EP-1910272-A1 | RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2008-04-16 | — | — | EP | disclosed |
| EP-1838696-A1 | NOVEL CYANOGUANIDINE COMPOUNDS | Leo Pharma A/S (DK) | 2007-10-03 | — | — | EP | disclosed |
| WO-2007009250-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006066584-A1 | NOVEL CYANOGUANIDINE COMPOUNDS | LEO PHARMA A/S (DK) | 2006-06-29 | — | — | WO | disclosed |
| US-6583156-B1 | Particularly adenosine A2A receptors; neurodegenerative disorders; 2,8-bis(trifluoromethyl)-alpha -(3-thienyl)-4-quinolinemethanol | VERNALIS RESEARCH LIMITED (GB) | 2003-06-24 | — | — | US | disclosed |
| CN-1067684-C | Imidazo [1,5-1] quinolines for treatment of anxiety and sleep disorders | PHAMACIA UPJOHN CO (US) | 2001-06-27 | — | — | CN | disclosed |
| EP-1107760-A2 | 4-QUINOLINEMETHANOL DERIVATIVES AS PURINE RECEPTOR ANTAGONISTS (I) | VERNALIS RESEARCH LIMITED (GB) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000013681-A2 | 4-QUINOLINEMETHANOL DERIVATIVES AS PURINE RECEPTOR ANTAGONISTS (I) | VERNALIS RESEARCH LIMITED (GB) | 2000-03-16 | — | — | WO | disclosed |
| CN-1135753-A | Imidazo [1, 5-a ] quinolines for the treatment of anxiety and sleep disorders | UPJOHN CO (US) | 1996-11-13 | — | — | CN | disclosed |
| US-4968803-A | FLUORINE AS OXIDANT | ALLIED-SIGNAL INC. (US) | 1990-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178505-A1 | Compounds for the Inhibition of Cellular Proliferation | MKI67, EIF2AK2, CDK2 | KDM4E 2418/4885MEN1 3017/4885KMT2A 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.